28 October 2022
Ondine Biomedical Inc.
("Ondine Biomedical", "Ondine" or the "Company")
PDMR Dealing
Ondine Biomedical Inc. (AIM: OBI), announces the following dealings by certain persons discharging managerial responsibilities ('PDMR') on 24 October 2022 and 25 October 2022:
On 24 October 2022, Vipul Shah, Chief Financial Officer of Ondine, purchased 15,000 ordinary shares with no par value each in the Company ("Ordinary Shares") at a price of 25 pence per share, and 10,000 Ordinary Shares at a price of 25.25 pence per share. Furthermore, on 25 October 2022, Mr Shah purchased 25,000 Ordinary Shares at a price of 25 pence per share. Following these purchases, Mr Shah's total interest in the Company is 50,000 Ordinary Shares, representing 0.026% of the total voting rights of the Company.
The notification below, made in accordance with the requirements of the UK Market Abuse Regulations, provide further detail in respect of the transaction as described above.
| 1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
| a) |
Name |
Vipul Shah |
||||||||||||
| 2. |
Reason for the Notification |
|||||||||||||
| a) |
Position/status |
PDMR (Chief Financial Officer) |
||||||||||||
| b) |
Initial notification/amendment |
Initial notification |
||||||||||||
| 3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
| a) |
Name |
Ondine Biomedical Inc. (the "Issuer") |
||||||||||||
| b) |
LEI |
9845005B69E07CGF4A56 |
||||||||||||
| 4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted |
|||||||||||||
| a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of no par value |
||||||||||||
| Identification code |
GB00BYX5K988 |
|||||||||||||
| b) |
Nature of the Transaction |
Purchase of ordinary shares |
||||||||||||
| c) |
Price(s) and volume(s) |
|
||||||||||||
| d) |
Aggregated information Aggregated volume Price |
Purchase of, in aggregate, 50,000 Ordinary Shares Average price of 25.05 pence |
||||||||||||
| e) |
Date of the transaction |
1. 24 October 2022 Purchase of 15,000 Ordinary Shares at 25 pence per share 2. 24 October 2022 3. 25 October 2022 |
||||||||||||
| f) |
Place of the transaction |
AIM (LSE) |
||||||||||||
For further Information, please visit: www.ondinebio.com or contact:
| Ondine Biomedical Inc. |
|
| Carolyn Cross, CEO |
+1 604 669 0555 |
|
|
|
| Strand Hanson Limited (Nominated and Financial Adviser) |
|
| James Harris, James Dance, Richard Johnson |
+44 (0) 20 7409 3494 |
|
|
|
| RBC Capital Markets (Joint Broker) |
|
| Rupert Walford, Kathryn Deegan |
+44 (0) 20 7653 4000 |
| |
|
| Singer Capital Markets (Joint Broker) |
|
| Aubrey Powell, Asha Chotai |
+44 (0)20 7496 3000 |
| |
|
| Vane Percy & Roberts (Media Contact) |
|
| Simon Vane Percy, Amanda Bernard |
+44 (0) 77 1000 5910 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.